Description

NSE notifies admission of Rights Entitlements (REs) of JFL Life Sciences Limited for trading on SME EMERGE segment from March 16, 2026, with renunciation window closing March 18, 2026.

Summary

NSE has admitted Rights Entitlements (REs) of JFL Life Sciences Limited for trading on the Capital Market segment (SME EMERGE) effective March 16, 2026. The REs, issued under the company’s ongoing Rights Issue, will trade under the symbol JFL-RE in the Trade to Trade segment in compulsory demat mode. A total of 32,995,323 REs are available for trading with a market lot size of 6,000.

Key Points

  • Symbol: JFL-RE; ISIN: INE0LA920015; Series: ST
  • 32,995,323 Rights Entitlements admitted for trading
  • Market lot size: 6,000 REs
  • Trading in Trade to Trade (T2T) segment, compulsory demat for all investors
  • Trading members must prominently disclaim in contract notes that REs are not ordinary shares
  • Unsubscribed and unrenounced REs will lapse after the Issue Closing Date

Regulatory Changes

No new regulatory changes introduced. The circular operates under existing Regulation 3.1.1 and Regulation 2.5.5 of the National Stock Exchange (Capital Market) Trading Regulations Part A.

Compliance Requirements

  • Trading members must inform all clients about the commencement of RE trading, specifying the ISIN and clarifying REs are not ordinary shares.
  • Contract notes/bills for RE purchases must carry a prominent disclaimer stating that purchasing REs only entitles the holder to participate in the Rights Issue or renounce before the issue closes.
  • Members must communicate that unsubscribed/unrenounced REs will lapse and be extinguished after the Issue Closing Date.

Important Dates

  • March 16, 2026: Commencement of RE trading on NSE SME EMERGE; circular effective date
  • March 16–18, 2026: Trading period for renunciation of Rights Entitlements
  • March 19, 2026: Date of suspension of RE trading

Impact Assessment

This circular has a moderate and time-limited impact, primarily affecting existing shareholders of JFL Life Sciences Limited who received Rights Entitlements. The 3-day trading window (March 16–18) provides a short opportunity for rights holders to renounce their entitlements on-market. The Trade to Trade settlement requirement limits speculative activity and ensures delivery-based transactions only. Investors who neither subscribe nor renounce their REs by the closing date will lose the value of those entitlements.

Impact Justification

Routine rights entitlement trading notification for a SME segment company with a short 3-day trading window; relevant primarily to existing shareholders and rights issue participants.